Our results are supported by a study that investigated ultrasound, CT, whole-body and liver MRI, and 18F-FDG-PET/CT for the detection of tumour recurrence and metastases in MTC patients with elevated serum calcitonin levels after initial treatment [32]. The gene discussed is CALCA; the disease is medullary thyroid gland carcinoma.